SCHEMBL2415348

SCHEMBL2415348

CC(C)(Sc1nc(CC(=O)O)cs1)C(=O)O

nearest known ligand 0.49

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ HSD17B10 Q99714 2/20 0.49
▸ GABRA5 P31644 1/20 0.49
▸ GABRB2 P47870 1/20 0.49
▸ ALDH1A1 P00352 4/20 0.42
▸ KDM4E B2RXH2 4/20 0.42
▸ HPGD P15428 3/20 0.42
▸ LMNA P02545 1/20 0.41
▸ PPARA Q07869 8/20 0.40
▸ GAA P10253 4/20 0.40
▸ MAPT P10636 2/20 0.39
▸ NPC1 O15118 1/20 0.39
▸ NFKB1 P19838 1/20 0.39
▸ RAB9A P51151 1/20 0.39
▸ NFKB2 Q00653 1/20 0.39
▸ RELA Q04206 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5563274 0.86 PPARA (0.41) HSD17B10GABRA5GABRB2ALDH1A1KDM4E
SCHEMBL12273172 0.85 HSD17B10 (0.43) HSD17B10GABRA5GABRB2ALDH1A1KDM4E
SCHEMBL2414685 0.85 HSD17B10 (0.43) HSD17B10GABRA5GABRB2ALDH1A1KDM4E
SCHEMBL2409115 0.84 PPARA (0.39) PPARAMAPT
SCHEMBL14451641 0.83 HSD17B10 (0.41) HSD17B10GABRA5GABRB2ALDH1A1KDM4E
SCHEMBL2417979 0.82 PPARA (0.39) HSD17B10GABRA5GABRB2PPARAMAPT
SCHEMBL2409605 0.81 MEN1 (0.57) HSD17B10ALDH1A1KDM4ELMNAGAA
SCHEMBL2418139 0.80 POLQ (0.41) ALDH1A1HPGDLMNAPPARAGAA
SCHEMBL9332045 0.79 HSD17B10 (0.56) HSD17B10GABRA5GABRB2ALDH1A1KDM4E
SCHEMBL10361187 0.79 HSD17B10 (0.59) HSD17B10GABRA5GABRB2ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8026370-B2 Peroxisome proliferator antagonist; hyperlipemia agents; arteriosclerosis; antiischemic agents MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-09-27 — — US disclosed
US-20080167307-A1 Carboxylic Acid Derivative Containing Thiazole Ring and Pharmaceutical Use Thereof MITSUBISHI PHAMA CORPORATION (JP) 2008-07-10 — — US disclosed
EP-1816128-A1 CARBOXYLIC ACID DERIVATIVE CONTAINING THIAZOLE RING AND PHARMACEUTICAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2007-08-08 — — EP disclosed
EP-1816128-A1 CARBOXYLIC ACID DERIVATIVE CONTAINING THIAZOLE RING AND PHARMACEUTICAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2007-08-08 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080167307-A1 Carboxylic Acid Derivative Containing Thiazole Ring and Pharmaceutical Use Thereof PPARA, PPARD, PPARG HSD17B10 66/4885GABRA5 399/4885GABRB2 486/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback